PMC:7347402 / 20808-22292 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T216","span":{"begin":152,"end":154},"obj":"http://purl.obolibrary.org/obo/CLO_0001236"},{"id":"T217","span":{"begin":750,"end":753},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T218","span":{"begin":926,"end":929},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T219","span":{"begin":1125,"end":1126},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T220","span":{"begin":1202,"end":1203},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T221","span":{"begin":1346,"end":1347},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T222","span":{"begin":1445,"end":1446},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The cumulative death rate within 28 days in all COVID-19 participants stratified in terms of FBG and CRB-65 score at admission overall is shown in Fig. 2a (ptrend \u003c 0.0001) and Fig. 2b (ptrend = 0.0020). Compared with patients with FBG \u003c6.1 mmol/l, mortality within 28 days was higher in those with FBG of 6.1–6.9 mmol/l (crude HR 2.06 [95% CI 1.20, 3.54]) and ≥7.0 mmol/l (crude HR 3.54 [95% CI 2.33, 5.38]), respectively (Table 2). Compared with patients with FBG of 6.1–6.9 mmol/l, mortality within 28 days was higher in those with FBG ≥7.0 mmol/l (crude HR 1.72 [95% CI 1.05, 2.84]). Meanwhile, compared with patients with CRB-65 score of 0, mortality within 28 days was higher in those with CRB-65 of 1–2 (crude HR 4.35 [95% CI 2.81, 6.72]) and 3–4 (crude HR 13.80 [95% CI 5.99, 31.80]), respectively (Table 2). Compared with patients with CRB-65 score of 1–2, mortality within 28 days was higher in those with CRB-65 of 3–4 (crude HR 3.18 [95% CI 1.46, 6.89]).\nFig. 2 Kaplan–Meier survival curves (showing cumulative mortality and 95% CI) for COVID-19 patients stratified in terms of FBG or CRB-65 score at admission. (a) Kaplan–Meier survival curves of all COVID-19 patients stratified by FBG; (b) Kaplan–Meier survival curves of all COVID-19 patients stratified by CRB-65 score; (c) Kaplan–Meier survival curves of COVID-19 patients with a CRB-65 score of 0, stratified by FBG; (d) Kaplan–Meier survival curves of COVID-19 patients with a CRB-65 score of \u003e0, stratified by FBG"}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T203","span":{"begin":0,"end":203},"obj":"Sentence"},{"id":"T204","span":{"begin":204,"end":433},"obj":"Sentence"},{"id":"T205","span":{"begin":434,"end":587},"obj":"Sentence"},{"id":"T206","span":{"begin":588,"end":816},"obj":"Sentence"},{"id":"T207","span":{"begin":817,"end":966},"obj":"Sentence"},{"id":"T208","span":{"begin":967,"end":1484},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The cumulative death rate within 28 days in all COVID-19 participants stratified in terms of FBG and CRB-65 score at admission overall is shown in Fig. 2a (ptrend \u003c 0.0001) and Fig. 2b (ptrend = 0.0020). Compared with patients with FBG \u003c6.1 mmol/l, mortality within 28 days was higher in those with FBG of 6.1–6.9 mmol/l (crude HR 2.06 [95% CI 1.20, 3.54]) and ≥7.0 mmol/l (crude HR 3.54 [95% CI 2.33, 5.38]), respectively (Table 2). Compared with patients with FBG of 6.1–6.9 mmol/l, mortality within 28 days was higher in those with FBG ≥7.0 mmol/l (crude HR 1.72 [95% CI 1.05, 2.84]). Meanwhile, compared with patients with CRB-65 score of 0, mortality within 28 days was higher in those with CRB-65 of 1–2 (crude HR 4.35 [95% CI 2.81, 6.72]) and 3–4 (crude HR 13.80 [95% CI 5.99, 31.80]), respectively (Table 2). Compared with patients with CRB-65 score of 1–2, mortality within 28 days was higher in those with CRB-65 of 3–4 (crude HR 3.18 [95% CI 1.46, 6.89]).\nFig. 2 Kaplan–Meier survival curves (showing cumulative mortality and 95% CI) for COVID-19 patients stratified in terms of FBG or CRB-65 score at admission. (a) Kaplan–Meier survival curves of all COVID-19 patients stratified by FBG; (b) Kaplan–Meier survival curves of all COVID-19 patients stratified by CRB-65 score; (c) Kaplan–Meier survival curves of COVID-19 patients with a CRB-65 score of 0, stratified by FBG; (d) Kaplan–Meier survival curves of COVID-19 patients with a CRB-65 score of \u003e0, stratified by FBG"}

LitCovid-PMC-OGER-BB

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T37596","span":{"begin":725,"end":733},"obj":"SP_7"},{"id":"T179","span":{"begin":757,"end":760},"obj":"PR:Q9SA52"},{"id":"T180","span":{"begin":805,"end":813},"obj":"SP_7"},{"id":"T13792","span":{"begin":830,"end":833},"obj":"PR:Q9SA52"},{"id":"T182","span":{"begin":904,"end":912},"obj":"SP_7"},{"id":"T183","span":{"begin":929,"end":932},"obj":"PR:Q9SA52"},{"id":"T184","span":{"begin":1049,"end":1057},"obj":"SP_7"},{"id":"T185","span":{"begin":1097,"end":1100},"obj":"PR:Q9SA52"},{"id":"T88719","span":{"begin":1164,"end":1172},"obj":"SP_7"},{"id":"T187","span":{"begin":1241,"end":1249},"obj":"SP_7"},{"id":"T10030","span":{"begin":1273,"end":1276},"obj":"PR:Q9SA52"},{"id":"T189","span":{"begin":1323,"end":1331},"obj":"SP_7"},{"id":"T190","span":{"begin":1348,"end":1351},"obj":"PR:Q9SA52"},{"id":"T27944","span":{"begin":1422,"end":1430},"obj":"SP_7"},{"id":"T192","span":{"begin":1447,"end":1450},"obj":"PR:Q9SA52"}],"text":"The cumulative death rate within 28 days in all COVID-19 participants stratified in terms of FBG and CRB-65 score at admission overall is shown in Fig. 2a (ptrend \u003c 0.0001) and Fig. 2b (ptrend = 0.0020). Compared with patients with FBG \u003c6.1 mmol/l, mortality within 28 days was higher in those with FBG of 6.1–6.9 mmol/l (crude HR 2.06 [95% CI 1.20, 3.54]) and ≥7.0 mmol/l (crude HR 3.54 [95% CI 2.33, 5.38]), respectively (Table 2). Compared with patients with FBG of 6.1–6.9 mmol/l, mortality within 28 days was higher in those with FBG ≥7.0 mmol/l (crude HR 1.72 [95% CI 1.05, 2.84]). Meanwhile, compared with patients with CRB-65 score of 0, mortality within 28 days was higher in those with CRB-65 of 1–2 (crude HR 4.35 [95% CI 2.81, 6.72]) and 3–4 (crude HR 13.80 [95% CI 5.99, 31.80]), respectively (Table 2). Compared with patients with CRB-65 score of 1–2, mortality within 28 days was higher in those with CRB-65 of 3–4 (crude HR 3.18 [95% CI 1.46, 6.89]).\nFig. 2 Kaplan–Meier survival curves (showing cumulative mortality and 95% CI) for COVID-19 patients stratified in terms of FBG or CRB-65 score at admission. (a) Kaplan–Meier survival curves of all COVID-19 patients stratified by FBG; (b) Kaplan–Meier survival curves of all COVID-19 patients stratified by CRB-65 score; (c) Kaplan–Meier survival curves of COVID-19 patients with a CRB-65 score of 0, stratified by FBG; (d) Kaplan–Meier survival curves of COVID-19 patients with a CRB-65 score of \u003e0, stratified by FBG"}